An observational study in Antibiotic Pharmacokinetics, sponsored by Karolinska University Hospital. Status unknown at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-24.
Sponsored by Karolinska University Hospital · Observational
The purpose of the study is to characterize the pharmacokinetics of meropenem and piperacillin in ICU-patients at the time of the first dose administration and to contrast that with the same measurements obtained in the same patient 2-3 days later during the course of ICU treatment.
Karolinska University Hospital is the lead sponsor of 275 studies on the registry; 54 are open to participants now.
Counted across the registry records on this site, refreshed daily.
ICU-patients.
Inclusion Criteria:
Exclusion Criteria (fullfilling any exlusion criteria means that patient cannot be included in the study):
As specified by study population, inclusion and exclusion criteria
Drug: Piperacillin/tazobactam, Meropenem
This is an observational study exploring the antibiotic plasma concentration profiles in ICU paitents after the first drug administration.
Volume of distribution
Apparent volume of distribution calculated from repeated plasma concentrations measurements and pharmacokinetic modelling.
Time frame: For the first antibiotic administration and if possible for a second administration 48-72 hour later.
Plasma clearance
Plasma clearance calculated from repeated plasma concentrations measurements and pharmacokinetic modelling.
Time frame: For the first antibiotic administration and if possible for a second administration 48-72 hour later.
Plasma antibiotic concentrations at mid and end of dosing interval
Plasma antibiotic concentrations at mid and end of dosing interval
Time frame: For the first antibiotic administration and if possible for a second administration 48-72 hour later.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Karolinska University Hospital